SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Li, Y. Articles by Lyerly, H. K. Search for Related Content PubMed PubMed Citation Articles by Li, Y. Articles by Lyerly, H. K. Related Collections Immunobiology Neoplasia Immunotherapy Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 October 2000, Vol. 96, No. 8, pp. 2828-2833 IMMUNOBIOLOGY Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells Yiwen Li, Maurizio Bendandi, Yuping Deng, Cynthia Dunbar, Nikhil Munshi, Sundar Jagannath, Larry W. Kwak, and H. Kim Lyerly From the Center for Genetic and Cellular Therapies, Departments of Surgery, Immunology, and Pathology, Duke University Medical Center, Durham, NC; the Department of Experimental Transplantation and Immunology, Medicine Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD; the Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD; and the Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AK. Immunoglobulin secreted by myeloma cells contains a unique antigenic determinant (idiotype [Id]) that may serve as a tumor-specific antigen. Although Id-protein-specific T-cell responses have been reported in patients with myeloma, it is not known whether primary myeloma tumor cells can present naturally processed Id peptides on their surface as a target. We immunized 2 healthy human stem-cell donors with Id proteins from their recipients. T cells from the immunized donors released high levels of T-helper 1-type cytokines in response to stimulation with myeloma cells from their recipients. The T-cell-mediated cytokine response to tumor cells was blocked by a major histocompatibility complex (MHC) class I monoclonal antibody, whereas the response to soluble Id protein was dependent on MHC class II. To investigate whether Id-specific CD8+ T cells can recognize and kill autologous myeloma cells, we generated T cells from peripheral blood mononuclear cells from a third patient with myeloma by means of in vitro stimulation with autologous dendritic cells pulsed with Id protein. Tumor-specific lysis of myeloma cells was demonstrated by the lack of killing of autologous nonmalignant B cells or natural killer-sensitive K562 cells. Lysis of autologous myeloma targets was restricted by MHC class I molecules. These data represent the first report of class I-restricted T-cell recognition of fresh autologous myeloma targets and formally demonstrate that human myeloma cells can serve as targets of an Id-specific T-cell response. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Hong, J. Qian, J. Yang, H. Li, L. W. Kwak, and Q. Yi Roles of Idiotype-Specific T Cells in Myeloma Cell Growth and Survival: Th1 and CTL Cells Are Tumoricidal while Th2 Cells Promote Tumor Growth Cancer Res., October 15, 2008; 68(20): 8456 - 8464. [Abstract] [Full Text] [PDF] T. A. Smith-Norowitz, J. Silverberg, K. B. Norowitz, M. H. Bluth, S. Chice, R. Joks, M. Nowakowski, and H. G. Durkin Two Distinct T Cell Subsets, CD4+ and CD8+CD60+, and Their Cytokines Are Required for In Vitro Induction of Human Ragweed-Specific Memory IgE Responses J. Immunol., October 1, 2008; 181(7): 4761 - 4769. [Abstract] [Full Text] [PDF] P. Serafini, S. Mgebroff, K. Noonan, and I. Borrello Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells Cancer Res., July 1, 2008; 68(13): 5439 - 5449. [Abstract] [Full Text] [PDF] A. O. Abdalla, P. Kokhaei, L. Hansson, H. Mellstedt, and A. Osterborg Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC) Ann. Onc., June 1, 2008; 19(6): 1172 - 1179. [Abstract] [Full Text] [PDF] M. Martin-Ayuso, J. Almeida, M. Perez-Andres, R. Cuello, J. Galende, M. I. Gonzalez-Fraile, G. Martin-Nunez, F. Ortega, M. J. Rodriguez, J. F. San Miguel, et al. Peripheral Blood Dendritic Cell Subsets from Patients with Monoclonal Gammopathies Show an Abnormal Distribution and Are Functionally Impaired Oncologist, January 1, 2008; 13(1): 82 - 92. [Abstract] [Full Text] [PDF] L. Hansson, A. O. Abdalla, A. Moshfegh, A. Choudhury, H. Rabbani, B. Nilsson, A. Osterborg, and H. Mellstedt Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients Clin. Cancer Res., March 1, 2007; 13(5): 1503 - 1510. [Abstract] [Full Text] [PDF] P. Horna, A. Cuenca, F. Cheng, J. Brayer, H.-W. Wang, I. Borrello, H. Levitsky, and E. M. Sotomayor In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity Blood, April 1, 2006; 107(7): 2871 - 2878. [Abstract] [Full Text] [PDF] O. Goodyear, K. Piper, N. Khan, J. Starczynski, P. Mahendra, G. Pratt, and P. Moss CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden Blood, December 15, 2005; 106(13): 4217 - 4224. [Abstract] [Full Text] [PDF] S. B. Rew, K. Peggs, I. Sanjuan, A. R. Pizzey, Y. Koishihara, S. Kawai, M. Kosaka, S. Ozaki, B. Chain, and K. L. Yong Generation of Potent Antitumor CTL from Patients with Multiple Myeloma Directed against HM1.24 Clin. Cancer Res., May 1, 2005; 11(9): 3377 - 3384. [Abstract] [Full Text] [PDF] Q. Yi and L. W. Kwak Monocyte-Derived Dendritic Cells: A Promising Armament for Immunotherapy in Human Malignancies Clin. Cancer Res., February 1, 2005; 11(3): 966 - 967. [Full Text] [PDF] S. S. Neelapu, S. Baskar, B. L. Gause, C. B. Kobrin, T. M. Watson, A. R. Frye, R. Pennington, L. Harvey, E. S. Jaffe, R. J. Robb, et al. Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen Clin. Cancer Res., December 15, 2004; 10(24): 8309 - 8317. [Abstract] [Full Text] [PDF] T. Azuma, T. Otsuki, K. Kuzushima, C. J. Froelich, S. Fujita, and M. Yasukawa Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes Clin. Cancer Res., November 1, 2004; 10(21): 7402 - 7412. [Abstract] [Full Text] [PDF] Y. Deng, Y. Jing, A. E. Campbell, and S. Gravenstein Age-Related Impaired Type 1 T Cell Responses to Influenza: Reduced Activation Ex Vivo, Decreased Expansion in CTL Culture In Vitro, and Blunted Response to Influenza Vaccination In Vivo in the Elderly J. Immunol., March 15, 2004; 172(6): 3437 - 3446. [Abstract] [Full Text] [PDF] M. Grube, K. Rezvani, A. Wiestner, H. Fujiwara, G. Sconocchia, J. J. Melenhorst, N. Hensel, G. E. Marti, L. W. Kwak, W. Wilson, et al. Autoreactive, Cytotoxic T Lymphocytes Specific for Peptides Derived from Normal B-Cell Differentiation Antigens in Healthy Individuals and Patients with B-Cell Malignancies Clin. Cancer Res., February 1, 2004; 10(3): 1047 - 1056. [Abstract] [Full Text] [PDF] H. K. Lyerly Tackling T-cell tumors Blood, October 1, 2003; 102(7): 2313 - 2313. [Full Text] [PDF] L. Hansson, H. Rabbani, J. Fagerberg, A. Osterborg, and H. Mellstedt T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma Blood, June 15, 2003; 101(12): 4930 - 4936. [Abstract] [Full Text] [PDF] T. Rasmussen, L. Hansson, A. Osterborg, H. E. Johnsen, and H. Mellstedt Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells Blood, June 1, 2003; 101(11): 4607 - 4610. [Abstract] [Full Text] [PDF] E. Orsini, R. Bellucci, E. P. Alyea, R. Schlossman, C. Canning, S. McLaughlin, P. Ghia, K. C. Anderson, and J. Ritz Expansion of Tumor-specific CD8+ T Cell Clones in Patients with Relapsed Myeloma after Donor Lymphocyte Infusion Cancer Res., May 15, 2003; 63(10): 2561 - 2568. [Abstract] [Full Text] [PDF] C. Milazzo, V. L. Reichardt, M. R. Muller, F. Grunebach, and P. Brossart Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA Blood, February 1, 2003; 101(3): 977 - 982. [Abstract] [Full Text] [PDF] M. V. Dhodapkar, J. Krasovsky, and K. Olson T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells PNAS, October 1, 2002; 99(20): 13009 - 13013. [Abstract] [Full Text] [PDF] G. Dotti, B. Savoldo, P. Yotnda, D. Rill, and M. K. Brenner Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40+ and CD40- plasmacytoma cells Blood, June 17, 2002; 100(1): 200 - 207. [Abstract] [Full Text] [PDF] J. Gong, S. Koido, D. Chen, Y. Tanaka, L. Huang, D. Avigan, K. Anderson, T. Ohno, and D. Kufe Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12 Blood, April 1, 2002; 99(7): 2512 - 2517. [Abstract] [Full Text] [PDF] M. Gorschluter, C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma Clin. Cancer Res., August 1, 2001; 7(8): 2195 - 2204. [Abstract] [Full Text] [PDF]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020